secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001171843-22-003323
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex Q1 net loss $0.49/share; cash $380.5M; barzolvolimab Ph2 starts Q2 2022
-------------------------------------------------------------------------------

- Net loss of $23.1M ($0.49 per share) vs $16.5M ($0.42) a year ago; revenue fell to $0.2M from $0.7M.
- Cash, cash equivalents and marketable securities $380.5M at March 31, 2022; sufficient to fund operations through 2025.
- R&D expenses increased to $17.1M from $12.7M; G&A expenses $6.9M vs $4.1M, driven by clinical and commercial planning.
- Phase 2 studies of barzolvolimab in chronic spontaneous and inducible urticaria to initiate Q2 2022; Phase 1b CSU data submitted to EAACI.
- Barzolvolimab expansion into eosinophilic esophagitis with Phase 2 planned Q4 2022; enrollment continues in prurigo nodularis and inducible urticaria.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184322003323/0001171843-22-003323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184322003323/f8k_050522.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-003323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer